Legionnaires disease
Abstract
Legionnaires disease, more formally known as legionellosis, is a relatively common form of severe pneumonia caused by Legionella, a genus of waterborne bacteria. Legionellosis is acquired by inhalation of legionellae from contaminated environmental sources. Legionella pneumophila serogroup 1 is responsible for more than 80% of cases in most countries. More than 1500 cases were reported in France in 2005. Initial diagnosis is based on tests for urinary antigens. The mortality rate for legionellosis depends on the promptness of appropriate antibiotic therapy. Macrolides (erythromycin or intravenous azithromycin, which is preferred to erythromycin for its better pharmacodynamic properties) and fluoroquinolones (levofloxacin) are the antibiotics of choice for severe legionellosis.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.